I think its a pretty binary event. The monotherapy indication is the closest to market. If it fails then the share price goes to cash or below to account for the ERT switch trial failing as well as cash burn (about 2.5 a share). If its positive then i'm thinking the convenience of an oral drug that's possibly going to be less cumbersome will make the market think that FOLD will own the close to 1B Fabry market and other LSD markets. The share price could rise substantially higher.
Where is the skepticism you are referring to? I have yet to see a bearish analyst on FOLD.
Market Data 
Markets 
AI
